RSS Feeds
Search

Out-licensing

Cancer - Novel Gene (TADG-12) (98-24)

University of Arkansas for Medical Sciences
Transmembrane Serine Protease Overexpressed in Ovarian Carcinoma

Mechanism of action

Extracellular Serine Protease

Full description

TADG-12 is a new member of the serine protease family. This novel Tumor Antigen Derived Gene, i.e. TADG, was identified by differential PCR display using both normal ovarian tissue and ovarian carcinoma. More specifically, TADG-12 was identified using primers to the conserved histidine (sense) and the conserved aspartic acid (antisense). Northern blot analysis utilizing cDNA probe from the 5' domain of TADG-12 revealed three transcripts of 2.6kb, 1.7kb, and 0.9kb. The presence of these transcript varients are noted to be overexpressed in several subtypes of ovarian carcinomas, and not in normal ovary.

Reference: Biochimica et Biophysica Acta 1502, (2000) 337 - 350

98-24

Development status

Preclinical

Patent information

US Patents #6,291,663; #6,294,663, #6,942,978; #7,265,216, #7,067,630 + National Filings

License Status: Exclusive Licensing Available in all Fields except Diagnostic

Type of business relationship sought

Additional Licensing Partner to further the commercialization of the Vaccine, Small Molecule, Antisense and Gene Therapy applications of this patented technology

Patent number

US6291663,US6294663,US6942978,US7265216,US7067630

Related reports

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us